Motley Fool Staff
the_motley_fool
Recent Articles by Motley Fool Staff

Apr 7, 2016
by Motley Fool Staff
Could Washington Throw Out Medivation's Xtandi Patents?
Members of Congress are lobbying for the NIH to use a rarely invoked law to invalidate exclusivity on Xtandi's patents, based on the idea that the high prices Medivation charges for it are harming American consumers.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.